Skin Cancer

>

Latest News

Adjuvant Dabrafenib/Trametinib Maintains Long-Term Survival Benefit in Stage III Melanoma
Adjuvant Dabrafenib/Trametinib Maintains Long-Term Survival Benefit in Stage III Melanoma

June 1st 2024

These data from the COMBI-AD trial represent the longest follow-up to date of adjuvant treatment for stage III melanoma.

Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit
Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

April 12th 2024

Doctor and nurse in medical meeting discussing strategic medical treatment plan together with report and laptop. Medical school workshop training concept in panoramic banner. Neoteric: © Summit Art Creations - stock.adobe.com
TIL Therapy for Advanced Melanoma Requires Nursing, Pharmacy Collaboration

March 6th 2024

AI-Powered Detection System for Skin Cancers Receives FDA Approval
AI-Powered Detection System for Skin Cancers Receives FDA Approval

February 18th 2024

FDA Approves TIL Therapy for Unresectable or Metastatic Melanoma
FDA Approves TIL Therapy for Unresectable or Metastatic Melanoma

February 16th 2024

Latest CME Events & Activities

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

View More

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

More News

© 2024 MJH Life Sciences

All rights reserved.